Fidelity Investments
SPRY icon

Fidelity Investments’s ARS Pharmaceuticals SPRY Stock Holding History

Fidelity Investments’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.8M Buy
349,164
+7,122
+2% +$61.3K ﹤0.01% 2634
2026
Q1 		$2.75M Sell
342,042
-56,917
-14% -$545K ﹤0.01% 2532
2025
Q4 		$4.65M Sell
398,959
-343,549
-46% -$3.34M ﹤0.01% 2311
2025
Q3 		$7.46M Sell
742,508
-824,502
-53% -$11.8M ﹤0.01% 2106
2025
Q2 		$27.3M Buy
1,567,010
+576,150
+58% +$8.31M ﹤0.01% 1591
2025
Q1 		$12.5M Sell
990,860
-111,365
-10% -$1.34M ﹤0.01% 1843
2024
Q4 		$11.6M Buy
1,102,225
+15,910
+1% +$223K ﹤0.01% 1889
2024
Q3 		$15.8M Buy
1,086,315
+997
+0.1% +$11.9K ﹤0.01% 1791
2024
Q2 		$9.24M Buy
1,085,318
+396
+0% +$3.51K ﹤0.01% 1884
2024
Q1 		$11.1M Sell
1,084,922
-117,393
-10% -$875K ﹤0.01% 1837
2023
Q4 		$6.59M Sell
1,202,315
-105,025
-8% -$460K ﹤0.01% 1975
2023
Q3 		$4.94M Sell
1,307,340
-3,357,438
-72% -$22M ﹤0.01% 2049
2023
Q2 		$31.3M Sell
4,664,778
-423,475
-8% -$2.83M ﹤0.01% 1454
2023
Q1 		$33.1M Sell
5,088,253
-281,109
-5% -$2.16M ﹤0.01% 1409
2022
Q4 		$45.8M Buy
5,369,362
+605,813
+13% +$3.93M ﹤0.01% 1287
2022
Q3 		$25.2M Buy
4,763,549
+1,045,097
+28% +$5.15M ﹤0.01% 1537
2022
Q2 		$15.8M Sell
3,718,452
-74,720
-2% -$261K ﹤0.01% 1754
2022
Q1 		$13.3M Buy
3,793,172
+39,435
+1% +$172K ﹤0.01% 1999
2021
Q4 		$25M Sell
3,753,737
-534,812
-12% -$4.35M ﹤0.01% 1721
2021
Q3 		$42.8M Sell
4,288,549
-399,419
-9% -$9.85M ﹤0.01% 1482
2021
Q2 		$145M Sell
4,687,968
-137,591
-3% -$4.41M 0.01% 952
2021
Q1 		$209M Buy
4,825,559
+1,384,255
+40% +$65.5M 0.02% 771
2020
Q4 		$156M Buy
+3,441,304
New +$115M 0.01% 853

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments's SPRY Position: Q2 2026 in Review

Fidelity Investments increased its ARS Pharmaceuticals (SPRY) stake by 2.1% in Q2 2026, buying an estimated $61.3K and bringing the position to 349,164 shares worth $2.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2634.

Fidelity Investments first reported a position in SPRY in Q4 2020 and has held it in 23 quarters since. The position peaked at $209M in Q1 2021. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Fidelity Investments held 349,164 shares of ARS Pharmaceuticals worth $2.8M as of Q2 2026.
  • Fidelity Investments bought 7,122 ARS Pharmaceuticals shares in Q2 2026, an estimated $61.3K.
  • ARS Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2634 holding.
  • Fidelity Investments first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Fidelity Investments's ARS Pharmaceuticals position peaked at $209M in Q1 2021.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.